Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dongrui R. Lu"'
Autor:
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2
Externí odkaz:
https://doaj.org/article/89451dd2a5dd43c39359872a65b6f791
Autor:
Zhou Zhu, Nicholas C. Turner, Sherene Loi, Fabrice André, Miguel Martin, Véronique Diéras, Karen A. Gelmon, Nadia Harbeck, Cathy Zhang, Joan Q. Cao, Zhengming Yan, Dongrui R. Lu, Ping Wei, Todd L. VanArsdale, Paul A. Rejto, Xin Huang, Hope S. Rugo, Sibylle Loibl, Massimo Cristofanilli, Richard S. Finn, Yuan Liu
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-10 (2022)
Abstract While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metasta
Externí odkaz:
https://doaj.org/article/43b2f5ee4b6d4217b08f6a0227d829bb
Autor:
Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematolog
Externí odkaz:
https://doaj.org/article/c9f4326e37ad41e7874ee10f377c5ba6
Autor:
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, Ave Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-19 (2019)
PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. We assessed the b
Externí odkaz:
https://doaj.org/article/27c93162d478480fa223e9d92b076529
Autor:
Dennis J. Slamon, Cynthia Huang Bartlett, Eric Gauthier, Dongrui R. Lu, Nadia Harbeck, Karen A. Gelmon, Seock-Ah Im, Véronique Diéras, Hope S. Rugo, Miguel Martin, Zhou Zhu, Yuan Liu, Richard S. Finn
Purpose:Preclinical data identified the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib as synergistic with antiestrogens in inhibiting growth of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fd2af1ff461666946fd880d68a934e
https://doi.org/10.1158/1078-0432.c.6528555.v1
https://doi.org/10.1158/1078-0432.c.6528555.v1
Autor:
Maggie Cheang, Mitch Dowsett, Mothaffar Rimawi, Stephen Johnston, Samuel Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Publikováno v:
Cancer Research. 82:PD2-07
Background Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients (pts) with breast cancer (BC) treated with chemotherapy, human epidermal growth factor receptor 2 (HER2) targeted therapies, and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b629f42dbff05fef9c0498b3fed539f
https://doi.org/10.1158/1538-7445.sabcs21-pd2-07
https://doi.org/10.1158/1538-7445.sabcs21-pd2-07
Autor:
Michael, Gnant, Amylou C, Dueck, Sophie, Frantal, Miguel, Martin, Hal J, Burstein, Richard, Greil, Peter, Fox, Antonio C, Wolff, Arlene, Chan, Eric P, Winer, Georg, Pfeiler, Kathy D, Miller, Marco, Colleoni, Jennifer M, Suga, Gabor, Rubovsky, Judith M, Bliss, Ingrid A, Mayer, Christian F, Singer, Zbigniew, Nowecki, Olwen, Hahn, Jacqui, Thomson, Norman, Wolmark, Kepa, Amillano, Hope S, Rugo, Guenther G, Steger, Blanca, Hernando Fernández de Aránguiz, Tufia C, Haddad, Antonia, Perelló, Meritxell, Bellet, Hannes, Fohler, Otto, Metzger Filho, Anita, Jallitsch-Halper, Kadine, Solomon, Céline, Schurmans, Kathy P, Theall, Dongrui R, Lu, Kathleen, Tenner, Christian, Fesl, Angela, DeMichele, Erica L, Mayer
Publikováno v:
Journal of Clinical Oncology. 40:282-293
PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbc01917bf87e41cb5637a9f1fd33c18
https://doi.org/10.1200/jco.21.02554
https://doi.org/10.1200/jco.21.02554
Autor:
Kathy Puyana Theall, A. Mori, Patrick Schnell, Karen A. Gelmon, Massimo Cristofanilli, Eustratios Bananis, Richard S. Finn, Dongrui R. Lu, Nicholas C. Turner, Hope S. Rugo, Eric Gauthier, Sherene Loi, Véronique Diéras, Marco Colleoni
Publikováno v:
The Oncologist
Background Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure. Patients and Methods Data were pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40a21d6edb68c7f1863afc1397ff4aa
https://doi.org/10.1002/onco.13684
https://doi.org/10.1002/onco.13684
Autor:
Eustratios Bananis, Sherene Loi, Eric Gauthier, Massimo Cristofanilli, Richard S. Finn, Kathy Puyana Theall, Hope S. Rugo, A. Mori, Dongrui R. Lu, Nicholas C. Turner, Patrick Schnell, Karen A. Gelmon, Marco Colleoni, Véronique Diéras
Publikováno v:
Cancer Research. 80:P1-19
Background Palbociclib (PAL) in combination with endocrine therapy (ET) was shown to be tolerable in a previous pooled analysis of the 3 PALOMA clinical trials. This new pooled, post hoc analysis examines the safety profile of PAL + ET using data fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faeccffdc181927469ffc8070c5889b4
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-16
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-16
Autor:
Yasuaki Muramatsu, Takashi Nagasawa, Satoshi Hashigaki, Shoichiro Ohtani, Shozo Ohsumi, Hiroji Iwata, Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Masakazu Toi, Chikako Shimizu, Dongrui R. Lu, Nobuaki Sato, Yoshiko Umeyama, Yuko Mori, Shinji Ohno, Yutaka Yamamoto, Hirofumi Mukai
Publikováno v:
International Journal of Clinical Oncology
Background In PALOMA-2, palbociclib–letrozole significantly improved progression-free survival (PFS) vs placebo–letrozole in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a349ba52728007743e64eb82a6b952c3
https://doi.org/10.1007/s10147-018-1353-9
https://doi.org/10.1007/s10147-018-1353-9